The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAFV600E inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 2, 2012, Pages

  Liu, Ruixin ^a   Liu, Dingxie ^a   Xing, Mingzhao ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE; MK 2206; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SELUMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG TARGETING; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; GROWTH INHIBITION; MOLECULAR PATHOLOGY; MONOTHERAPY; ONCOGENE; OUTCOME ASSESSMENT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYROID CANCER; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; CARCINOMA; CELL PROLIFERATION; DOWN-REGULATION; DRUG ANTAGONISM; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; GLUTAMIC ACID; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; INDOLES; MUTANT PROTEINS; ONCOGENE PROTEIN V-AKT; PHOSPHORYLCHOLINE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; THYROID NEOPLASMS; TUMOR CELLS, CULTURED; VALINE;

EID: 84863012398     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1054     Document Type: Article

References (40)

1. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762 (Pubitemid 350294294)
2. Tang KT, Lee CH 2010 BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J Chin Med Assoc 73:113-128
3. Paes JE, Ringel MD 2008 Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am 37:375-387, viii-ix (Pubitemid 351698084)
4. Xing M 2010 Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 20:697-706
5. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V, Xing M 2007 Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 13:1161-1170 (Pubitemid 46424056)
6. Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, Garcia-Rostan G 2008 BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf) 68:618-634 (Pubitemid 351388702)
7. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI 2008 Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 93:278-284
8. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK, Xing M 2008 Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93:3106-3116
9. Xing M 2008 Recent advances in molecular biology of thyroid cancer and their clinical implications. Otolaryngol Clin North Am 41:1135-1146, ix
10. Xing M 2009 Genetic-targeted therapy of thyroid cancer: a real promise. Thyroid 19:805-809
11. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ 2008 Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31-42 (Pubitemid 351931094)
12. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB 2008 Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708-4713
13. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely Jr PE, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684
14. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris 3rd JC, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C 2010 Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 11:962-972
15. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB 2010 Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819
16. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K 2010 Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596-599
17. Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G 2010 Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab 95:450-455
18. Xing J, Liu R, Xing M, Trink B 2011 The BRAF(T1799A) mutation confers sensitivity of thyroid cancer cells to the BRAF(V600E) inhibitor PLX4032 (RG7204). Biochem Biophys Res Commun 404:958-962
19. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt SG 2008 Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26:2139-2146
20. Elrod HA, Lin YD, Yue P, Wang X, Lonial S, Khuri FR, Sun SY 2007 The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther 6:2029-2038 (Pubitemid 47052493)
21. Liu D, Hou P, Liu Z, Wu G, Xing M 2009 Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 69:7311-7319
22. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H 2010 MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9:1956-1967
23. Liu R, Liu D, Trink E, Bojdani E, Ning G, Xing M 2011 The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway. J Clin Endocrinol Metab 96:E577-E585
24. Gills JJ, Dennis PA 2009 Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 11:102-110
25. Tolcher AW, Yap TA, Fearen I, Taylor A, Carpenter C, Brunetto AT, Beeram M, Papadopoulos K, Yan L, de Bono J 2009 A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor. J Clin Oncol 27:15s
26. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK 2003 Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2:1093-1103
27. Chou TC, Talalay P 1983 Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 4:450-454
28. Liu D, Xing J, Trink B, Xing M 2010 BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer 127:2965-2973
29. Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA 2010 Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One 5:e14124
30. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA 2010 Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70:8736-8747
31. Sgambato A, Cittadini A, Faraglia B, Weinstein IB 2000 Multiple functions of p27(Kip1) and its alterations in tumor cells: a review. J Cell Physiol 183:18-27 (Pubitemid 30130221)
32. Kumar A, Fillmore HL, Kadian R, Broaddus WC, Tye GW, Van Meter TE 2009 The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma. Mol Cancer Res 7:1813-1821
33. Patel V, Lahusen T, Sy T, Sausville EA, Gutkind JS, Senderowicz AM 2002 Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res 62:1401-1409 (Pubitemid 34407799)
34. Rahmani M, Anderson A, Habibi JR, Crabtree TR, Mayo M, Harada H, Ferreira-Gonzalez A, Dent P, Grant S 2009 The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. Blood 114:4507-4516
35. Friday BB, Adjei AA 2008 Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 14:342-346 (Pubitemid 351226098)
36. Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M, Nelkin BD2007 Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab 92:4712-4718 (Pubitemid 350223448)
37. Hou P, Liu D, Ji M, Liu Z, Engles JM, Wahl RL, Xing M 2009 Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications. PLoS One 4:e6200
38. Pal SK, Reckamp K, Yu H, Figlin RA 2010 Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 19:1355-1366
39. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG, Anderson KC 2006 Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107:4053-4062 (Pubitemid 43726814)
40. Fu L, Kim YA, Wang X, Wu X, Yue P, Lonial S, Khuri FR, Sun SY 2009 Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res 69:8967-8976